World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , 

World Journal of Pharmaceutical
and Medical Research

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 4.103

ICV : 78.6

Abstract

IMMUNOHISTOCHEMISTRY PROFILING OF BREAST MALIGNANCIES IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA

Dr. Ponnuswamy Karkuzhali* and Dr. Vijay David Raj. R.

ABSTRACT

Immunohistochemistry (IHC), is a method for localizing specific antigens in cells based on antigen-antibody recognition; Immunohistochemistry (IHC) is used to characterize intracellular proteins or various cell surfaces in all tissues. Individual markers or more often panels of various marker proteins can be used to characterize various tumour subtypes, confirm tissue of origin, distinguish metastatic from primary tumour and provide additional information which may be important for prognosis, predicting response to therapy or evaluating residual tumour post-treatment. Aim and Objective: To classify the malignancies of the breast using the recent classification by immunohistochemistry. Methods: Cases of Malignant tumour of the breast reported by H&E staining from 2013 to 2016 were stained for ER, PR and Her2/Neu receptors and the results are tabulated. Results: Out of 110 breast malignancy cases, Her2 Neu was 36.36%, Luminal A was 18.18 %, Luminal B was 13.63%, and Triple Negative/Basal type was 31.81%. Conclusion: Molecular sub-classification of breast carcinomas are feasible in a tertiary care centre by using basic immunohistochemical markers.

[Full Text Article]

Powered By WJPMR | All Right Reserved

WJPMR